Malaria vaccine
US9028843B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 8, 2014 |
| Grant date | May 12, 2015 |
| Priority date | — |
| Expiry date | Jul 8, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/822
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant.X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5 (1)(In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.